Sapanisertib (BioDeep_00000859084)

   


代谢物信息卡片


INK 128 (MLN0128)

化学式: C15H15N7O (309.1338)
中文名称: 沙帕色替
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N
InChI: InChI=1S/C15H15N7O/c1-7(2)22-14-11(13(16)18-6-19-14)12(21-22)8-3-4-10-9(5-8)20-15(17)23-10/h3-7H,1-2H3,(H2,17,20)(H2,16,18,19)

描述信息

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2201 - mTOR Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
Sapanisertib (INK-128; MLN0128; TAK-228) is an orally available, ATP-dependent mTOR1/2 inhibitor with an IC50 of 1 nM for mTOR kinase.
Sapanisertib (INK-128; MLN0128; TAK-228) is an orally available, ATP-dependent mTOR1/2 inhibitor with an IC50 of 1 nM for mTOR kinase.

同义名列表

5 个代谢物同义名

INK 128 (MLN0128); Sapanisertib; INK-128; MLN0128; TAK-228



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Bradley A McGregor, Wanling Xie, Elio Adib, Walter M Stadler, Yousef Zakharia, Aijai Alva, M Dror Michaelson, Shilpa Gupta, Elaine T Lam, Subrina Farah, Amin H Nassar, Xiao X Wei, Kerry L Kilbridge, Lauren Harshman, Sabina Signoretti, Lynette Sholl, David J Kwiatkowski, Rana R McKay, Toni K Choueiri. Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. JCO precision oncology. 2022 02; 6(?):e2100448. doi: 10.1200/po.21.00448. [PMID: 35171658]
  • Martin H Voss, Michael S Gordon, Monica Mita, Brian Rini, Vicky Makker, Teresa Macarulla, David C Smith, Andrés Cervantes, Igor Puzanov, Roberto Pili, Ding Wang, Shadia Jalal, Shubham Pant, Manish R Patel, Rachel L Neuwirth, Aaron Enke, Yaping Shou, Farhad Sedarati, Douglas V Faller, Howard A Burris. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. British journal of cancer. 2020 11; 123(11):1590-1598. doi: 10.1038/s41416-020-01041-x. [PMID: 32913286]
  • Chirag Patel, Sanjay Goel, Manish R Patel, Lakshmi Rangachari, Jayson D Wilbur, Yaping Shou, Karthik Venkatakrishnan, A Craig Lockhart. Phase 1 Study to Evaluate the Effect of the Investigational Anticancer Agent Sapanisertib on the QTc Interval in Patients With Advanced Solid Tumors. Clinical pharmacology in drug development. 2020 10; 9(7):876-888. doi: 10.1002/cpdd.808. [PMID: 32488989]
  • Denise Rageot, Thomas Bohnacker, Anna Melone, Jean-Baptiste Langlois, Chiara Borsari, Petra Hillmann, Alexander M Sele, Florent Beaufils, Marketa Zvelebil, Paul Hebeisen, Wolfgang Löscher, John Burke, Doriano Fabbro, Matthias P Wymann. Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders. Journal of medicinal chemistry. 2018 11; 61(22):10084-10105. doi: 10.1021/acs.jmedchem.8b01262. [PMID: 30359003]
  • Chen Li, Jian-Feng Cui, Min-Bin Chen, Chao-Ying Liu, Feng Liu, Qian-De Zhang, Jian Zou, Pei-Hua Lu. The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent. Cancer biology & therapy. 2015; 16(1):34-42. doi: 10.4161/15384047.2014.972274. [PMID: 25692620]
  • Norisuke Shibuya, Ken-ichi Inoue, Genki Tanaka, Kazumi Akimoto, Keiichi Kubota. Augmented pentose phosphate pathway plays critical roles in colorectal carcinomas. Oncology. 2015; 88(5):309-19. doi: 10.1159/000369905. [PMID: 25591719]
  • S Schenone, C Brullo, F Musumeci, M Radi, M Botta. ATP-competitive inhibitors of mTOR: an update. Current medicinal chemistry. 2011; 18(20):2995-3014. doi: 10.2174/092986711796391651. [PMID: 21651476]
  • . . . . doi: . [PMID: 32353859]